Research Paper Volume 11, Issue 6 pp 1716—1732

Elevated FPR confers to radiochemoresistance and predicts clinical efficacy and outcome of metastatic colorectal cancer patients

Figure 4. Survival comparison of the patient received different treatments in the high and low FPR subgroups and the dynamic change of FPR during the treatment. (a) Kaplan-Meier curve of OS within the patient received different treatment in low-FPR subgroup; (b) Kaplan-Meier curve of OS within the patient received different treatment in high-FPR subgroup; (c) dynamic change of FPR in left- and right-sided mCRC patients; (d) dynamic change of FPR of mCRC patient undergoing chemotherapy or palliative resection Abbreviation within in Panels 4a-b: A: radiochemotherapy; B: palliative resection plus radiochemotherapy; C: bevacizumab plus radiochemotherapay. Abbreviation within in Panels 4c-d: 1: the diagnostic time; 2: one month after the first treatment; 3: regular examination without disease progression; 4: one month before disease progression; 5: time of imaging confirmed progression; 6: within three months before death.